# Ga-68-PSMA-11 in High-risk Prostate Cancer

> **NCT03362359** · PHASE1,PHASE2 · COMPLETED · sponsor: **German Cancer Research Center** · enrollment: 173 (actual)

## Conditions studied

- High-risk Prostate Cancer
- Prostate Cancer
- Prostate Cancer Metastatic
- Lymphnode Metastasis

## Interventions

- **DRUG:** Ga-68-PSMA-11

## Key facts

- **NCT ID:** NCT03362359
- **Lead sponsor:** German Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-09
- **Primary completion:** 2020-07-06
- **Final completion:** 2020-07-06
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2020-07-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03362359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03362359, "Ga-68-PSMA-11 in High-risk Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03362359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*